Designing Nanomedicine based on Gender Differences

The innovative idea of nanomedicine targets a particular site with tiny yet potent medications. But, for the vast heterogeneous population, this novel and successful therapeutic strategy establishes the idea that there is a “one size fits all” solution1. Due to this frequency, the results propose a major strain on economic variability and public health2-3. However, other characteristics such as sex, age, and lifestyle are sometimes overlooked4. And from a historical perspective, sex-specific characteristics are mostly ignored among them. So, a discernible gap inthe scientific research has been created due to male prejudice5. Even as a precautionary measure, the United States government outlawed ten prescribed medications in 1997 and 2000, eight of which are significantly more dangerous for women than men6. In the era of nanomedicine, the market output will have an impact on integrating biological sex as an independent variable in research and development, which will, in turn, determine the success of advanced therapies for the future1.